RxDoctor Payments Data

Su Wang, MD

Internal Medicine · New York, NYNPI 1972639755

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (48.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Gilead accounts for 89.6% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $6,310 and has fallen 90.8% since, to $584 in 2025. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,598in general payments, 2019–2025

Across 142 payments — averaging $88.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$11K
  • Pfizer$251
  • GSK$229
  • Novo Nordisk$145
  • Dynavax Technologies Corporation$145
  • Abbott$109
  • plus $426 from 12 others
$351,784in research payments, 2019–2025

Across 3 payments — averaging $117,261 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$352K

What the payments were for

  • Consulting fees$2,26018%
  • Travel & lodging$6,06248%
  • Food & beverage$2,49420%
  • Education$1,78214%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,598 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York →

Medicare billing

Part B allowed, 2024
$18,173
Medicare patients
89
Services billed
222

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide13$12,096
GlyxambiEmpagliflozin/Linagliptin11$6,611
Entecavir16$1,659
SynthroidLevothyroxine Sodium11$1,520
Atorvastatin Calcium93$683
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide26$376
Losartan Potassium71$346
Amlodipine Besylate70$323
Metformin Hcl35$276
Metformin Hcl ErMetformin Hcl49$260
Rosuvastatin Calcium15$233
Tamsulosin Hcl19$232
Zolpidem Tartrate30$219
Levothyroxine Sodium25$207
Pravastatin Sodium14$152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$145$12,09613 claims
Boehringer IngelheimGlyxambi$88$6,61111 claims
AbbVieSynthroid$44$1,52011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →